Angiotensin receptor blockers: current status and future prospects

Area of Science:

• Cardiovascular Medicine
• Nephrology
• Pharmacology

Background:

• The renin-angiotensin system plays a critical role in cardiovascular and renal homeostasis.
• Angiotensin receptor blockers (ARBs) are established treatments for hypertension and related conditions.
• ARBs offer excellent tolerability and 24-hour blood pressure control with renal benefits.

Purpose of the Study:

• To review the established benefits of ARBs in managing hypertension and related diseases.
• To explore the potential benefits of ARBs in special patient populations.
• To discuss the emerging role of combination therapy with ARBs and ACE inhibitors.

Main Methods:

• Review of existing clinical data and ongoing studies on ARBs.
• Analysis of the physiological mechanisms of the renin-angiotensin system blockade.
• Evaluation of preliminary findings on dual renin-angiotensin system blockade.

Main Results:

• ARBs reduce morbidity and mortality in hypertension, heart failure, myocardial infarction, stroke, diabetic nephropathy, and chronic kidney disease.
• ARBs demonstrate excellent tolerability and provide sustained 24-hour hypertension control.
• Preliminary data suggest potential benefits of combining ARBs with ACE inhibitors for enhanced cardio- and nephroprotection.

Conclusions:

• ARBs are valuable agents for hypertension and associated conditions due to their efficacy and tolerability.
• Further investigation is required to establish ARB efficacy in specific populations like heart failure with preserved ejection fraction, atrial fibrillation, cognitive dysfunction, and kidney transplant recipients.
• Combination therapy with ARBs and ACE inhibitors warrants further study to optimize renin-angiotensin system blockade and patient outcomes.